Firm
With the US privacy landscape more fragmented and active than ever and federal legislation stalled, lawyers at Sheppard Mullin explain how states are taking bold steps to define their own regimes
A vote to be held in 2026 could create Hogan Lovells Cadwalader, a $3.6bn giant with 3,100 lawyers across the Americas, EMEA and Asia Pacific
Varuni Paranavitane of Finnegan and IP counsel Lisa Ribes compare and contrast two recent AI copyright decisions from Germany and the UK
The new court has drastically changed the German legal market, and the Munich-based firm, with two recent partner hires, is among those responding
Recently published Special Focus articles
Recently published Special Focus articles
-
Sponsored by Anand and AnandAchuthan Sreekumar of Anand and Anand draws on a recent High Court of Delhi ruling on the unauthorised use of Ratan Tata’s identity to consider how Indian jurisprudence protects well-known personal names -
Sponsored by Tahota Law FirmCharles Feng, Lian Xue, and Chenxi Cui of Tahota Law Firm draw on the case and several other legal disputes to explore the fractious relationship between games console emulators and manufacturers
-
Sponsored by Liu, Shen & AssociatesJun Qiu of Liu, Shen & Associates analyses two recent CNIPA decisions that provide insights into the application of the good faith principle in patent re-examination and invalidation procedures in China
-
Sponsored by TOPPAN Digital IPThe team at TOPPAN Digital IP believe there are key flaws in current intellectual property systems and services. Managing IP hears how the company’s STREAM IP platform is aimed at addressing them
-
Sponsored by Liu, Shen & AssociatesDongguo Liang of Liu, Shen & Associates says DeepSeek should take swift action to address ‘insufficient planning’ in its intellectual property protection strategy and an ‘underdeveloped’ patent portfolio
-
Sponsored by Wanhuida Intellectual PropertyYue Guan of Wanhuida Intellectual Property considers the CNIPA’s evidentiary standards after its invalidation of a patent for the crystalline form of lemborexant and explains the implications for pharmaceutical patent strategies in China
